US2016052918A1PendingUtilityA1

Small compounds targeting tacc3

37
Assignee: JAPAN FOUND CANCERPriority: May 2, 2012Filed: Sep 25, 2015Published: Feb 25, 2016
Est. expiryMay 2, 2032(~5.8 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/02A61P 35/00A61K 31/4465C07D 405/14A61K 31/4025A61K 31/4409C07D 311/16A61K 31/445A61K 31/37C07D 403/14C07D 401/14A61K 31/5377C07D 407/04
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.

Claims

exact text as granted — not AI-modified
1 . A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a cancer targeting at TACC3 and/or a TACC3-TOGp complex: 
       
         
           
           
               
               
           
         
         wherein R 1  represents 
       
       
         
           
           
               
               
           
         
         OAc, NEt 2 , NMe(CH 2 CH 2 OH), NH(CH 2 CH 2 NMe 2 ), NEt(CH 2 CH 2 NMe 2 ), N(CH 2 CH 2 OMe) 2 , N + O − (CH 2 CH 2 OMe) 2 , NMe(CH 2 ) 3 Me, or N(CH 2 CH 2 Me) 2 ; R 2  represents Ac or H; and R 3  represents H, Cl, F, or Br. 
       
     
     
         2 . The compound or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer, targeting at TACC3 and/or a TACC3-TOGp complex according to  claim 1 , wherein
 the cancer targeting TACC3 is colon cancer, ovary cancer, uterine cancer, breast cancer, esophagus cancer, lymphoma, glioma, prostate cancer, kidney cancer, or melanoma.   
     
     
         3 . A method for producing an anticancer agent composition, comprising
 mixing a compound or a pharmaceutically acceptable salt thereof according to  claim 1  with a pharmaceutically acceptable excipient.   
     
     
         4 . The compound or the pharmaceutically acceptable salt thereof for use in the treatment of a cancer, targeting at TACC3 and/or a TACC3-TOGp complex according to  claim 1 , wherein the compound or the pharmaceutically acceptable salt thereof is selected from the group consisting of:

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.